Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas

Cancer Research

Volumn 59, Issue 15, 1999, Pages 3783-3789

  Harada, Hironobu ^a   Nakagavva, Kou ^a   Iwata, Shinji ^a   Saito, Masahiro ^a   Kumon, Yoshiaki ^a   Sakaki, Saburo ^a   Sato, Kohji ^a   Hamada, Katsuyuki ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; PROTEIN P16; PROTEIN P21; PROTEIN P53; VASCULOTROPIN;

AMINO ACID SUBSTITUTION; ANGIOGENESIS; ANIMAL CELL; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG POTENCY; GENE EXPRESSION REGULATION; GLIOMA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

ADENOVIRUSES, HUMAN; BRAIN NEOPLASMS; CELL CYCLE; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; DNA, COMPLEMENTARY; ENDOTHELIAL GROWTH FACTORS; GENES, P16; GENES, P53; GENETIC VECTORS; GLIOMA; HUMANS; LYMPHOKINES; NEOVASCULARIZATION, PATHOLOGIC; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0033178714     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Folkman, J. Tumor angiogenesis: therapeutic implications. N. Engl. J. Med., 285: 1182-1186, 1971.
2. Abdulrauf, S. I., Edvardsen, K., Ho, K. L., Yang, X. Y., Rock, J. P., and Rosenblum, M. L. Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J. Neurosurg., 88: 513-520, 1998.
3. Silbergeld, D. L., Ali-Osman, F., and Winn, H. R. Induction of transformational changes in normal endothelial ceils by cultured human astrocytoma cells. J. Neurosurg., 75: 604-612, 1991.
4. Plate, K. H., and Risau, W. Angiogenesis in malignant gliomas. Glia, 15: 339-347, 1995.
5. Ferrara, N., and Henzel, W. J. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem. Biophys. Res. Commun., 161: 851-858, 1989.
6. Senger, D. R., Galli, S. J., Dvorak, A. M., Perruzzi, C. A., Harvey, V. S., and Dvorak, H. F. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (Washington DC), 219: 983-985, 1983.
7. Hsu, S. C., Volpert, O. V., Steck, P. A., Mikkelsen, T., Polverini, P. J., Rao, S., Chou, P., and Bouck, N. P. Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res., 56: 5684-5691, 1996.
8. Van Meir, E. G., Polverini, P. J., Chazin, V. R., Su Huang, H. J., de Tribolet, N., and Cavenee, W. K. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat. Genet., 8: 171-176, 1994.
9. Mukhqpadhyay, D., Tsiokas, L., and Sukhatme, V. P. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res., 55: 6161-6165, 1995.
10. Bouvet, M., Ellis, L. M., Nishizaki, M., Fujiwara, T., Liu, W., Bucana, C. D., Fang, B., Lee, J. J., and Roth, J. A. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res., 58: 2288-2292, 1998.
11. Fontaninl, G., Boldrini, L., Vignati, S., Chine, S., Basolo, F., Silvestri, V., Lucchi, M., Mussi, A., Angeletti, C. A., and Bevilacqua, G. Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-tnediated angiogenesis in non-small cell lung carcinoma. Eur. J. Cancer, 34: 718-723, 1998.
12. Crew, J. P., O'Brien, T., Bradburn, M., Fuggle, S., Bicknell, R., Cranston, D., and Harris, A. L. Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. Cancer Res., 57: 5281-5285, 1997.
13. Louis, D. N. A molecular genetic model of astrocytoma histopathology. Brain Pathol., 7: 755-764, 1997.
14. 14: Schmidt, E. E., Ichimura, K., Reifenberger, G., and Collins, V. P. CDKN2 (p16/ MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res., 54: 6321-6324, 1994.
15. Ueki, K., Ono, Y., Henson, J. W., Efird, J. T., von Deimling, A., and Louis, D. N. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. Cancer Res., 56: 150-153, 1996.
16. Jen, J., Harper, J. W., Bigner, S. H., Bigner, D. D., Papadopoulos, N., Markowitz, S., Willson, J. K. V., Kinzler, K. W., and Vogelstein, B. Deletion of p16 and p15 genes in brain tumors. Cancer Res., 54: 6353-6358, 1994.
17. Hamada, K., Sakaue, M., Alemany, R., Zhang, W. W., Horio, Y., Roth, J. A., and Mitchell, M. F. Adenovirus-mediated transfer of HPV 16 E6/E7 antisense RNA to human cervical cancer cells. Gynecol. Oncol., 63: 219-227, 1996.
18. Serrano, M., Hannon, G. J., and Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (Lond.), 366: 704-707, 1993.
19. Fueyo, J., Gomez-Manzano, C., Yung, W. A., Clayman, G. L., Liu, T. J., Bruner, J., Levin, V. A., and Kyritsis, A. P. Adenovirus-mediated p16/CDKN2 gene transfer induces growth arrest and modifies the transformed phenotype of glioma cells. Oncogens, 12: 103-110, 1996.
20. INK4 or retinoblastoma protein (pRb) or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res., 55: 4833-4836, 1995.
21. Gomez-Manzano, C., Fueyo, J., Kyritsis, A. P., Steck, P. A., Roth, J. A., McDonnell, T. J., Steck, K. D., Levin, V. A., and Yung, W. K. A. Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res., 55: 694-699, 1996.
22. Hamada, K., Alemany, R., Zhang, W. W., Hittelman, W. N., Lotan, R., Roth, J. A., and Mitchell, M. F. Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res., 56: 3047-3054, 1996.
23. Viglietto, G., Romano, A., Maglione, D., Rambaldi, M., Paoletti, I., Lago, C. T., Califano, D., Monaco, C., Mineo, A., Santelli, G., Manzo, G., Botti, G., Chiappetta, G., and Persico, M. O. Neovascularization in human germ cell tumors correlates with a marked increase in the expression of the vascular endothelial growth factor but not the placenta-derived growth factor. Oncogene, 13: 577-587, 1996.
24. Iijima, K., Yoshikawa, N., and Nakamura, H. Activation-induced expression of vascular permeability factor by human peripheral T cells: a non-radioisotopic semi-quantitative reverse transcription-polymerase chain reaction assay. J. Immunol. Methods, 196: 199-209, 1996.
25. Abe, T., Okamura, K., Ono, M., Kohno, K., Mori, T., Hori, S., and Kuwano, M. Induction of vascular endothelial tubular morphogenesis by human glioma cells. A model system for tumor angiogenesis. J. Clin. Investig., 92: 54-61, 1993.
26. Oikawa, T., Sasaki, M., Inose, M., Shimamura, M., Kuboki, H., Hirano, S., Kumagai, H., Ishizuka, M., and Takeuchi, T. Effects of cytogenin, a novel microbial product, on embryonic and tumor cell-induced angiogenic responses in vivo. Anticancer Res., 17: 1881-1886, 1997.
27. Rastinejad, P., Polverini, P. J., and Bouck, N. P. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene. Cell, 50: 345-355, 1989.
28. Arap, W., Nishikawa, R., Furnari, F. B., Cavenee, W. K., and Huang, H. J. S. Replacement of the p16/CDKN2 gene suppresses human glioma cell growth. Cancer Res., 55: 1351-1354, 1995.
29. INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. Oncogene, 16: 265-272, 1998.
30. INK4/CDKN2 and p53 genes cooperate to induce apoptotic tumor cell death. Nat. Med., 3: 313-319, 1997.
31. Chintala, S. K., Fueyo, J., Gomez-Manzano, C., Venkaiah, B., Bjerkvig, R., Yung, W. K. A., Sawaya, R., Kyritsis, A. P., and Rao, J. S. Adenovirus-mediated p16/ CDKN2 gene transfer suppresses glioma invasion in vitro. Oncogene, 15: 2049-2057, 1997.
32. Nishimori, H., Shiratsuchi, T., Urano, T., Kimura, Y., Kiyono, K., Tatsumi, K., Yoshida, S., Ono, M., Kuwano, M., Nakamura, Y., and Tokino, T. A novel brain-specific p53-target gene, BAI1, containing thrombospondin type 1 repeats inhibits experimental angiogenesis. Oncogene, 15: 2145-2150, 1997.
33. Walker, M. D., Green, S. B., Byar, D. P., Alexander, E., Jr., Batzdorf, U., Brooks, W. H., Hunt, W. E., MacCarty, C. S., Mahaley, M. S., Jr., Mealey, J., Jr., Owens, G., Ransohoff, J., II, Robertson, J. T., Shapiro, W. R., Smith, K. R., Jr., Wilson, C. B., and Strike, T. A. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N. Engl. J. Med., 303: 1323-1329, 1980.
34. th ed., pp. 219-247. London: Edward Arnold, 1989.
35. Tanaka, T., Cao, Y., Folkman, J., and Fine, H. A. Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res., 58: 3362-3369, 1998.
36. Boehm, T., Folkman, J., Browder, T., and O'Reilly, M. S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature (Lond.), 390: 404-407, 1997.